David Parrot bought $40k of SCTX
Chief Financial Officer at Scribe Therapeutics, Inc.. 2,666 shares at an average of $15.00, traded Jul 23, 2026, filed Jul 27, 2026.
Score components
- +22RoleCFO
- +6Trade size$40k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- +15Cluster6 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002127908-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 23, 2026 | POpen-market purchase Common Stockindirect: By Spouse | +1,333 | $15.00 | $20k | 1,333 | Jul 27, 2026 |
| Jul 23, 2026 | POpen-market purchase Common Stockindirect: By Child | +1,333 | $15.00 | $20k | 1,333 | Jul 27, 2026 |
| Mar 13, 2026 | AGrant or award Stock Option (Right to Buy)derivative | +8,909 | $0.00 | $0 | 8,909 | Jul 27, 2026 |
| Jul 23, 2026 | AGrant or award Stock Option (Right to Buy)derivative | +109,426 | $0.00 | $0 | 109,426 | Jul 27, 2026 |
| Jul 23, 2026 | AGrant or award Performance-based Stock Option (Right to Buy)derivative | +109,426 | $0.00 | $0 | 109,426 | Jul 27, 2026 |
Related signals
Other insiders at Scribe Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Scribe Therapeutics, Inc. | AH Bio Fund II, L.P. owner | $5.0M 333,333 shares | +16% | |
| 65Notable | Scribe Therapeutics, Inc. | Carl L Gordon director | $15M 1,000,000 shares | +287% | |
| 60Notable | Scribe Therapeutics, Inc. | Orbimed Advisors LLC director | $15M 1,000,000 shares | +287% | |
| 65Notable | Scribe Therapeutics, Inc. | Behzad Aghazadeh director, owner, other | $36M 2,391,238 shares | +343% | |
| 44Moderate | Scribe Therapeutics, Inc. | Svetlana Lucas Chief Business Officer | $45k 3,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.